Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08:14 | Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity | 153 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
Mi | Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity | 211 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
Mi | Hemogenyx Pharma Plc - Exercise of Warrants and Issue of Equity | 3 | RNS | ||
Di | Hemogenyx Pharmaceuticals to issue convertible loan notes | 1 | Seeking Alpha | ||
HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
Mo | Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes | 217 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
Mo | Hemogenyx Pharmaceuticals raises £620,000 via convertible loan notes | 2 | Investing.com | ||
Mo | Hemogenyx Pharmaceuticals nimmt 620.000 £ über Wandelanleihen auf | 8 | Investing.com Deutsch | ||
Mo | Hemogenyx Pharma Plc - Issue of convertible loan notes | 1 | RNS | ||
29.08. | Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender | 167 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / August 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory... ► Artikel lesen | |
29.08. | Hemogenyx Pharma Plc - Result of Audit Tender | 1 | RNS | ||
26.08. | Hemogenyx stock rises on PS570,000 fundraise for Chimeric trials | 2 | Alliance News | ||
26.08. | Hemogenyx Pharmaceuticals PLC: Hemogenyx raises £570,000 and Director's Dealing | 213 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
26.08. | Hemogenyx Pharma Plc - Hemogenyx raises £570,000 and Director's Dealing | 2 | RNS | ||
15.08. | Hemogenyx completes first dose cohort in leukemia CAR-T trial | 3 | Investing.com | ||
15.08. | Hemogenyx Pharmaceuticals PLC - Third Patient Treated with HG-CT-1 CAR-T Therapy | 166 | ACCESS Newswire | Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS... ► Artikel lesen | |
15.08. | Hemogenyx Pharma Plc - Third Patient Treated with HG-CT-1 CAR-T Therapy | - | RNS | ||
31.07. | Hemogenyx Pharma Plc - Total Voting Rights | - | RNS | ||
29.07. | Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £250,000 and Director's Dealing | 371 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
29.07. | Hemogenyx Pharma Plc - Placing to Raise £250,000 and Director's Dealing | - | RNS | ||
16.07. | Hemogenyx Pharmaceuticals PLC: Hemogenyx Awarded Grant | 227 | ACCESS Newswire | Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing LONDON, UK / ACCESS Newswire / July 16, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
INNOCAN PHARMA | - | - | Innocan Pharma: Endspurt zum Nasdaq-Listing?! | ||
WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
MYDECINE INNOVATIONS GROUP | 0,002 | 0,00 % | Aquis Stock Exchange: Withdrawal from Trading - Mydecine Innovations Group Inc. | Aquis Stock Exchange
Aquis Stock Exchange: Withdrawal from Trading 02-Apr-2025 / 07:00 GMT/BST
The issuer is solely responsible for the content of this... ► Artikel lesen | |
BAYER | 28,380 | -0,68 % | DAX schwächer, Gold stark: Inflationsdaten, Alibaba, Siemens, Infineon, Bayer, Nvidia im Fokus | Am Donnerstag ist der DAX bei 24.039,92 Zählern kaum verändert aus dem Handel gegangen. Es fehlt an Impulsen, die weder Nvidia noch Konjunkturdaten liefern konnten. Und auch zum Start in den letzten... ► Artikel lesen | |
NOVO NORDISK | 47,590 | -1,18 % | Druck auf Novo Nordisk wächst: Teva greift mit Generikum an | Die Erholung der Aktie von Novo Nordisk ist zuletzt ins Stocken geraten. Wenig förderlich war dabei auch die Meldung, dass Teva Pharmaceuticals in den USA eine Zulassung für eine generische Version... ► Artikel lesen | |
MERCK KGAA | 109,20 | +0,65 % | Merck KGaA-Aktie: Kurs heute nahezu konstant (107,70 €) | An der deutschen Börse ist die Aktie von Merck derzeit unauffällig. Das Papier kostete zuletzt 107,70 Euro. Eine minimale Verteuerung von 0,14 Prozent zeigt die Kurstafel für die Aktie von Merck an.... ► Artikel lesen | |
SANOFI | 79,40 | +1,20 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für die Aktien von Sanofi von 90 auf 110 Euro angehoben und die Papiere von "Hold" auf "Buy" hochgestuft. Amlitelimab könnte ein... ► Artikel lesen | |
GSK | 17,010 | +0,12 % | GSK PLC - Director/PDMR Shareholding | ||
AQUESTIVE THERAPEUTICS | 5,055 | 0,00 % | FDA Confirms Direct Review Path For Aquestive's Allergy Treatment | ||
METSERA | 36,330 | 0,00 % | Metsera, Inc.: Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress | MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog)... ► Artikel lesen | |
PFIZER | 20,950 | -0,45 % | Pharma-Duell der Giganten: Bayer vs. Pfizer - welcher Titel bietet Anlegern mehr Gewinnpotential? | Der Pharmagigant Bayer AG ist jedem Anleger ein Begriff - dennoch lohnen sich oft Blicke über den Tellerrand hinaus, ob allenfalls noch ein anderer Branchenkonkurrent das bessere Investment wäre. Ein... ► Artikel lesen | |
HARROW | 36,190 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Second-Quarter 2025 Financial Results | Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA... ► Artikel lesen | |
CURANEX PHARMACEUTICALS | 7,070 | 0,00 % | Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering | Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and... ► Artikel lesen | |
ELI LILLY | 632,00 | -0,57 % | Neues Abnehmmittel kommt!: Vorsicht Novo Nordisk & Eli Lilly - Teva bringt "Abnehm-Generika" auf US-Markt! | Novo Nordisk und Eli Lilly bekommen Konkurrenz: Teva steigt mit einem Generikum in den US-Markt für Abnehmpräparate ein. Mit der FDA-Zulassung steigt der israelische Pharmariese in den milliardenschweren... ► Artikel lesen |